i n f l a r x

Loading

Press Release

Home Investors Press Releases Press Release

InflaRx Provides Update on Planned Phase III Study Design in Pyoderma Gangrenosum with Vilobelimab and Status of its EUA Application in Critically Ill COVID-19 Patients

Jan 05, 2023

Time to read 4 Minutes

Download PDF

Back